These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 24100689

  • 21. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 22. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
    Labrie F.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():144-56. PubMed ID: 24925260
    [Abstract] [Full Text] [Related]

  • 23. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V, Flamand V, Crouzet S, Ploussard G.
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [Abstract] [Full Text] [Related]

  • 24. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J, Taylor AR, Divine GW, Hafron JM, Hwang C.
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [Abstract] [Full Text] [Related]

  • 25. Hormonal Therapy for Prostate Cancer.
    Desai K, McManus JM, Sharifi N.
    Endocr Rev; 2021 May 25; 42(3):354-373. PubMed ID: 33480983
    [Abstract] [Full Text] [Related]

  • 26. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.
    J Clin Oncol; 2009 Aug 10; 27(23):3742-8. PubMed ID: 19470933
    [Abstract] [Full Text] [Related]

  • 27. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.
    Urologia; 2010 Aug 10; 77(2):71-83. PubMed ID: 20890863
    [Abstract] [Full Text] [Related]

  • 28. Androgen pathway resistance in prostate cancer and therapeutic implications.
    Maughan BL, Antonarakis ES.
    Expert Opin Pharmacother; 2015 Aug 10; 16(10):1521-37. PubMed ID: 26067250
    [Abstract] [Full Text] [Related]

  • 29. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.
    Eur J Cancer; 2014 Jan 10; 50(1):78-84. PubMed ID: 24074764
    [Abstract] [Full Text] [Related]

  • 30. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug 10; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 31. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wülfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R.
    Lancet Oncol; 2020 Nov 10; 21(11):1513-1525. PubMed ID: 32926841
    [Abstract] [Full Text] [Related]

  • 32. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.
    Lancet Oncol; 2018 Jan 10; 19(1):76-86. PubMed ID: 29248236
    [Abstract] [Full Text] [Related]

  • 33. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 34. [Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].
    Berlin A, Fernández MI.
    Rev Med Chil; 2015 Feb 01; 143(2):223-36. PubMed ID: 25860365
    [Abstract] [Full Text] [Related]

  • 35. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
    Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV.
    Cancer Treat Rev; 2015 Dec 01; 41(10):884-92. PubMed ID: 26342718
    [Abstract] [Full Text] [Related]

  • 36. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J.
    Eur Urol; 2017 Jan 01; 71(1):1-3. PubMed ID: 27471164
    [Abstract] [Full Text] [Related]

  • 37. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW.
    Lancet Oncol; 2022 Oct 01; 23(10):1297-1307. PubMed ID: 36063830
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
    McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME.
    Clin Genitourin Cancer; 2017 Aug 01; 15(4):463-471. PubMed ID: 27890446
    [Abstract] [Full Text] [Related]

  • 39. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.
    Eur Urol; 2019 Mar 01; 75(3):368-373. PubMed ID: 30773204
    [Abstract] [Full Text] [Related]

  • 40. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May 01; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.